Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
NEW YORK, March 20, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Middle District of North Carolina on behalf of investors who purchased Argos Therapeutics, Inc. ("Argos") (NASDAQ:ARGS) securities between February 7, 2014 and February 21, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/argos-therapeutics-inc. There is no cost or obligation to you.
According to the complaint, Argos issued materially false and/or misleading statements, causing the stock to trade at artificially inflated prices; following the release of adverse information, shares of Argos plummeted, damaging investors. In particular, the complaint alleges that Argos issued materially false and/or misleading information regarding the success and potential of its drug candidate AGS-003 (rocapuldencel-T).
On February 22, 2017, despite positive statements made by the Company, Argos then announced that the ADAPT study would be discontinued for futility. Following this news, shares of Argos fell approximately 66% to close at $1.48 per share on February 22, 2017.
If you suffered a loss in Argos you have until May 15, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/argos-therapeutics-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
